U.S. flag

An official website of the United States government

NM_000138.5(FBN1):c.4466A>G (p.Asn1489Ser) AND Marfan syndrome

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Jun 15, 2023
Review status:
3 stars out of maximum of 4 stars
reviewed by expert panel
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003235201.1

Allele description [Variation Report for NM_000138.5(FBN1):c.4466A>G (p.Asn1489Ser)]

NM_000138.5(FBN1):c.4466A>G (p.Asn1489Ser)

Gene:
FBN1:fibrillin 1 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
15q21.1
Genomic location:
Preferred name:
NM_000138.5(FBN1):c.4466A>G (p.Asn1489Ser)
Other names:
NM_000138.5(FBN1):c.4466A>G; p.Asn1489Ser
HGVS:
  • NC_000015.10:g.48468528T>C
  • NG_008805.2:g.182261A>G
  • NM_000138.5:c.4466A>GMANE SELECT
  • NP_000129.3:p.Asn1489Ser
  • NP_000129.3:p.Asn1489Ser
  • LRG_778t1:c.4466A>G
  • LRG_778:g.182261A>G
  • LRG_778p1:p.Asn1489Ser
  • NC_000015.9:g.48760725T>C
  • NM_000138.4:c.4466A>G
Protein change:
N1489S
Links:
dbSNP: rs1057518501
NCBI 1000 Genomes Browser:
rs1057518501
Molecular consequence:
  • NM_000138.5:c.4466A>G - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Marfan syndrome (MFS)
Synonyms:
MARFAN SYNDROME, TYPE I; Marfan syndrome type 1; Marfan's syndrome; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0007947; MedGen: C0024796; Orphanet: 284963; Orphanet: 558; OMIM: 154700

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV003933714ClinGen FBN1 Variant Curation Expert Panel, ClinGen
reviewed by expert panel

(Assertion Criteria VCEP FBN1 Version 1)
Uncertain significance
(Jun 15, 2023)
germlinecuration

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedcuration

Details of each submission

From ClinGen FBN1 Variant Curation Expert Panel, ClinGen, SCV003933714.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedcurationnot provided

Description

The NM_000138 c.4466A>G variant is a missense variant in FBN1 predicted to cause a substitution of asparagine by serine at amino position 1489. This variant has not been reported in the literature but has been reported in ClinVar three times as a variant of uncertain significance (Variation ID: 373598). This variant lies in a critical calcium binding site within a calcium-binding EGF domain; however, since asparagine to serine substitutions in these positions might be tolerated (PMID: 31227806) the PM1 criterion has not been used. It is not present in gnomAD v2.1.1 nor v3.1.2 (PM2_supporting; https://gnomad.broadinstitute.org/). Computational prediction tools and conservation analysis are unclear about the predicted impact of this variant (REVEL = 0.556). The constraint z-score for missense variants affecting FBN1 is 5.06 (PP2). Another missense variant at the same position (p.Asn1489Lys) is classified as likely pathogenic (PM5; PMIDs: 20082464, 26621581; 21542060). Due to the insufficient evidence, this variant is classified as of uncertain significance for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen FBN1 VCEP: PM2_supporting, PP2, PM5.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024